View ValuationAdvanced Enzyme Technologies 将来の成長Future 基準チェック /26Advanced Enzyme Technologies利益と収益がそれぞれ年間10%と12.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に12.2% 10.2%なると予測されています。主要情報10.0%収益成長率10.16%EPS成長率Chemicals 収益成長19.4%収益成長率12.3%将来の株主資本利益率12.20%アナリストカバレッジLow最終更新日05 Feb 2026今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to ₹265Down from ₹333, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹274. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹8.50 for next year compared to ₹10.70 last year.Price Target Changed • Apr 27Price target increased to ₹380Up from ₹333, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹305. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹11.30 for next year compared to ₹13.09 last year.すべての更新を表示Recent updatesReported Earnings • May 11Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹15.08 (up from ₹11.72 in FY 2025). Revenue: ₹7.81b (up 23% from FY 2025). Net income: ₹1.69b (up 29% from FY 2025). Profit margin: 22% (up from 21% in FY 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year.お知らせ • May 02Advanced Enzyme Technologies Limited to Report Q4, 2026 Results on May 09, 2026Advanced Enzyme Technologies Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 09, 2026Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹348, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years.Reported Earnings • Feb 01Third quarter 2026 earnings released: EPS: ₹3.80 (vs ₹3.36 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.80 (up from ₹3.36 in 3Q 2025). Revenue: ₹1.72b (up 1.7% from 3Q 2025). Net income: ₹425.0m (up 13% from 3Q 2025). Profit margin: 25% (up from 22% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jan 23Advanced Enzyme Technologies Limited to Report Q3, 2026 Results on Jan 31, 2026Advanced Enzyme Technologies Limited announced that they will report Q3, 2026 results on Jan 31, 2026お知らせ • Nov 04Advanced Enzyme Technologies Limited to Report Q2, 2026 Results on Nov 12, 2025Advanced Enzyme Technologies Limited announced that they will report Q2, 2026 results on Nov 12, 2025Valuation Update With 7 Day Price Move • Aug 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹305, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 21% over the past three years.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Independent Director Vandana Tilak was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 25Advanced Enzyme Technologies Limited to Report Q1, 2026 Results on Aug 02, 2025Advanced Enzyme Technologies Limited announced that they will report Q1, 2026 results on Aug 02, 2025Upcoming Dividend • Jul 16Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 23 July 2025. Payment date: 29 August 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 1.6%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).Reported Earnings • Jul 08Full year 2025 earnings released: EPS: ₹11.72 (vs ₹11.92 in FY 2024)Full year 2025 results: EPS: ₹11.72 (down from ₹11.92 in FY 2024). Revenue: ₹6.37b (up 2.1% from FY 2024). Net income: ₹1.31b (down 1.6% from FY 2024). Profit margin: 21% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year.Declared Dividend • Jun 11Dividend of ₹1.20 announcedShareholders will receive a dividend of ₹1.20. Ex-date: 23rd July 2025 Payment date: 29th August 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 38% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.Declared Dividend • May 15Dividend of ₹4.00 announcedShareholders will receive a dividend of ₹4.00. Ex-date: 16th May 2025 Payment date: 12th June 2025 Dividend yield will be 1.8%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has increased by an average of 37% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.お知らせ • May 13+ 2 more updatesAdvanced Enzyme Technologies Limited, Annual General Meeting, Jul 30, 2025Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 30, 2025.New Risk • Feb 13New major risk - Revenue and earnings growthEarnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Feb 09Third quarter 2025 earnings released: EPS: ₹3.36 (vs ₹3.74 in 3Q 2024)Third quarter 2025 results: EPS: ₹3.36 (down from ₹3.74 in 3Q 2024). Revenue: ₹1.69b (up 5.1% from 3Q 2024). Net income: ₹376.5m (down 9.9% from 3Q 2024). Profit margin: 22% (down from 26% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 01Advanced Enzyme Technologies Limited to Report Q3, 2025 Results on Feb 08, 2025Advanced Enzyme Technologies Limited announced that they will report Q3, 2025 results on Feb 08, 2025Valuation Update With 7 Day Price Move • Nov 16Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹380, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 17% over the past three years.Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹2.94 (vs ₹3.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.94 (down from ₹3.08 in 2Q 2024). Revenue: ₹1.46b (down 7.4% from 2Q 2024). Net income: ₹328.3m (down 4.6% from 2Q 2024). Profit margin: 23% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (₹52m sold).お知らせ • Oct 31Advanced Enzyme Technologies Limited to Report Q2, 2025 Results on Nov 09, 2024Advanced Enzyme Technologies Limited announced that they will report Q2, 2025 results on Nov 09, 2024Recent Insider Transactions • Sep 16Insider recently sold ₹51m worth of stockOn the 11th of September, Mangala Kabra sold around 100k shares on-market at roughly ₹509 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹68m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹534, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 38% over the past three years.Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹468, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years.Reported Earnings • Aug 11First quarter 2025 earnings released: EPS: ₹3.05 (vs ₹2.58 in 1Q 2024)First quarter 2025 results: EPS: ₹3.05 (up from ₹2.58 in 1Q 2024). Revenue: ₹1.62b (up 9.7% from 1Q 2024). Net income: ₹341.5m (up 19% from 1Q 2024). Profit margin: 21% (up from 20% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year.お知らせ • Aug 02Advanced Enzyme Technologies Limited to Report Q1, 2025 Results on Aug 10, 2024Advanced Enzyme Technologies Limited announced that they will report Q1, 2025 results on Aug 10, 2024お知らせ • Jul 27Advanced Enzyme Technologies Approves Final Dividend for the Financial Year Ended March 31, 2024Advanced Enzyme Technologies Limited at its 35th AGM held on July 25, 2024 approved final Dividend (INR 1.10 per Equity Share) on the Equity Shares of 2 each, for the financial year ended March 31, 2024.Upcoming Dividend • Jul 11Upcoming dividend of ₹1.10 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 24 August 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.3%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%).Reported Earnings • Jul 05Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.24b (up 15% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 21% (up from 20% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.お知らせ • Jun 28Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024, at 10:00 Indian Standard Time.Recent Insider Transactions • Jun 26Insider recently sold ₹11m worth of stockOn the 20th of June, Chandrakanth Kumar Rathi sold around 29k shares on-market at roughly ₹392 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.Recent Insider Transactions • Jun 22Insider recently sold ₹6.9m worth of stockOn the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹13m more than they bought in the last 12 months.Recent Insider Transactions • Jun 20Insider recently sold ₹6.9m worth of stockOn the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹4.9m more than they bought in the last 12 months.Declared Dividend • May 15Final dividend of ₹4.00 announcedShareholders will receive a dividend of ₹4.00. Ex-date: 17th May 2024 Payment date: 5th June 2024 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 39% per year over the past 7 years and payments have been stable during that time. Earnings per share has grown by 3.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 13Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.61b (up 22% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 20% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year.お知らせ • May 12+ 1 more updateAdvanced Enzyme Technologies Limited Recommends Final Dividend for the Financial Year 2023-2024Advanced Enzyme Technologies Limited announced that at its board meeting held on May 11, 2024, recommended a final dividend at 55% that is INR1.1 per equity share on the face value of INR 2 each for the financial year 2023-2024, subject to the approval of the Shareholders at the upcoming 35th Annual General Meeting of the Company (AGM). The final dividend, if approved /declared by the Shareholders at 35th AGM, will be paidon and from the second day from the date of AGM.お知らせ • May 06Advanced Enzyme Technologies Limited to Report Q4, 2024 Results on May 11, 2024Advanced Enzyme Technologies Limited announced that they will report Q4, 2024 results on May 11, 2024お知らせ • Mar 07Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) acquired additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 millionAdvanced Enzyme Technologies Limited (NSEI:ADVENZYMES) agreed to acquire additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million on February 10, 2024. Advanced Enzyme currently holds 89.83% stake in Jc Biotech and post completion of the transaction Advanced Enzyme will hold 95.72% stake in Jc Biotech. Jc Biotech reported turnover of INR 502 million and loss after tax of INR 18.42 million for FY2022-23. Board of Advanced Enzyme approved the transaction. The transaction is expected to close on March 31, 2024. Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) completed the acquisition of additional 5.89% stake in Jc Biotech Private Limited on March 5, 2024.Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹3.74 (vs ₹2.63 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.74 (up from ₹2.63 in 3Q 2023). Revenue: ₹1.75b (up 23% from 3Q 2023). Net income: ₹417.7m (up 42% from 3Q 2023). Profit margin: 24% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Feb 05Advanced Enzyme Technologies Limited to Report Q3, 2024 Results on Feb 10, 2024Advanced Enzyme Technologies Limited announced that they will report Q3, 2024 results on Feb 10, 2024New Risk • Dec 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.お知らせ • Nov 01Advanced Enzyme Technologies Limited to Report Q2, 2024 Results on Nov 07, 2023Advanced Enzyme Technologies Limited announced that they will report Q2, 2024 results on Nov 07, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹2.58 (vs ₹1.60 in 1Q 2023)First quarter 2024 results: EPS: ₹2.58 (up from ₹1.60 in 1Q 2023). Revenue: ₹1.47b (up 22% from 1Q 2023). Net income: ₹288.1m (up 61% from 1Q 2023). Profit margin: 20% (up from 15% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.お知らせ • Aug 13Advanced Enzyme Technologies Declares Final Dividend for the Financial Year Ended March 31, 2023Advanced Enzyme Technologies Limited at the AGM held on August 12, 2023 declared final Dividend (INR 1 per Equity Share) on the Equity Shares of 2each, for the financial year ended March 31, 2023.お知らせ • Aug 05Advanced Enzyme Technologies Limited to Report Q1, 2024 Results on Aug 12, 2023Advanced Enzyme Technologies Limited announced that they will report Q1, 2024 results on Aug 12, 2023Upcoming Dividend • Jul 28Upcoming dividend of ₹1.00 per share at 1.2% yieldEligible shareholders must have bought the stock before 04 August 2023. Payment date: 11 September 2023. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%).Reported Earnings • Jul 15Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.41b (up 2.1% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 20% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.お知らせ • Jul 09Advanced Enzyme Technologies Limited Proposes Dividend Payable on or After August 16, 2023The 34th Annual General Meeting ("AGM") of the Advanced Enzyme Technologies Limited will be held on August 12, 2023. Pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to letter dated May 13,2023 intimating that Dividend of INR 1 per Equity Share of INR 2 each for the financial year 2022-23 (FY23) recommended by the Board of Directors of the Company, it is hereby informed that Record Date has been fixed as August 05, 2023, for the purpose of ascertaining the entitlement of the Members to the said final dividend for Fiscal 2023, if approved (declared) at the 34th AGM. If the Dividend is approved by the Members as mentioned above: the said Dividend shall be paid on or after August 16, 2023 to the Members whose names appear in the Register of Members or as beneficial owners as on August 05, 2023; and in the cases where the ECS mandates of the Members are not available to enable the payment of Dividend electronically, the Dividend warrant/drafts/cheques shall be sent in due course.Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Director Nitin Deshmukh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • Jun 18Chairman recently bought ₹142m worth of stockOn the 15th of June, Vasant Rathi bought around 515k shares on-market at roughly ₹275 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 05Chairman recently bought ₹2.7m worth of stockOn the 31st of May, Vasant Rathi bought around 10k shares on-market at roughly ₹275 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months.Reported Earnings • May 14Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.66b (up 6.9% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 19% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.お知らせ • May 14+ 1 more updateAdvanced Enzyme Technologies Limited Announces Board ChangesThe board of directors of Advanced Enzyme Technologies Limited meeting held on May 13, 2023, appointed Ms. Vandana R. Tilak as an Additional Director (Independent), with effect from July 01, 2023, to hold office up to the date of upcoming Annual General Meeting of the Company ("AGM") or the date up to which AGM shall be held, whichever is earlier. Subject To Approve the Members at the upcoming AGM of the Company, Ms. Vandana R. Tilak shall hold office as an Independent Director for a period of 5 (five) years effective from July 01, 2023. Ms. Vandana R. Tilak is a social entrepreneur and visionary with exceptional sales, fundraising, and marketing skills to lead teams and pivot on the ever- changing revenue generation landscape. Ms. Vandana has launched several companies in film making, Ayurveda, real estate and the family engineering firm Almex USA Inc. Almex is a niche company that provides cast house technology solutions for manufacturing aerospace grade aluminum alloys. She is currently working as Director and CEO for the Akshaya Patra Foundation USA. The Board noted that Mr. Rajesh Sharma, an Independent Director, whose tenure of five years as an Independent Director on the Board of the Company ends with effect from August 10, 2023, has conveyed his unwillingness to get re-appointed for the second term, considering his pre-occupation and increased responsibilities in his professional engagements. Accordingly, he shall cease to be Director on the Board of the Company after the expiry of his existing tenure effective from August 10, 2023.お知らせ • May 07Advanced Enzyme Technologies Limited to Report Q4, 2023 Results on May 13, 2023Advanced Enzyme Technologies Limited announced that they will report Q4, 2023 results on May 13, 2023Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹2.63 (vs ₹2.46 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.63 (up from ₹2.46 in 3Q 2022). Revenue: ₹1.51b (up 13% from 3Q 2022). Net income: ₹294.4m (up 7.1% from 3Q 2022). Profit margin: 20% (down from 21% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.お知らせ • Feb 05Advanced Enzyme Technologies Limited to Report Q3, 2023 Results on Feb 11, 2023Advanced Enzyme Technologies Limited announced that they will report Q3, 2023 results on Feb 11, 2023お知らせ • Jan 04Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited.Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 4.83% stake in JC Biotech Private Limited for INR 68 million on November 11, 2022. Advanced Enzyme Technologies Limited will acquire 1 million shares of JC Biotech Private Limited. JC Biotech Private Limited reported Turnover of INR 504 million and Net income of INR 73 million in year ending March 31, 2022. The transaction was approved by Advanced Enzyme Technologies Limited Board of directors. The transaction was expected to complete on January 31, 2023. Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited on January 3, 2022.Price Target Changed • Nov 16Price target decreased to ₹265Down from ₹333, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹274. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹8.50 for next year compared to ₹10.70 last year.お知らせ • Nov 05Advanced Enzyme Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022Advanced Enzyme Technologies Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 11, 2022Recent Insider Transactions • Sep 23Insider recently sold ₹100m worth of stockOn the 19th of September, Savita Rathi sold around 372k shares on-market at roughly ₹270 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months.お知らせ • Aug 20+ 1 more updateAdvanced Enzyme Technologies Limited Announces Appointment of Mr. Nitin Jagannath Deshmukh as an Independent Director of the CompanyAdvanced Enzyme Technologies Limited at its Annual General Meeting (AGM) held on August 19, 2022 approved appointment of Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Independent Director of the Company.Upcoming Dividend • Aug 04Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 11 August 2022. Payment date: 18 September 2022. Payout ratio is a comfortable 9.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (0.7%).お知らせ • Jul 30+ 1 more updateAdvanced Enzyme Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022Advanced Enzyme Technologies Limited proposed to declare final dividend of INR 1/- on the equity shares of INR 2/- each for the financial year ended March 31, 2022 at the annual general meeting to be held on August 19, 2022.Reported Earnings • Jul 29Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹10.70 (down from ₹13.07 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 7.3%, compared to a 15% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 22Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022, at 10:00 Indian Standard Time.Reported Earnings • May 22Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹10.70 (down from ₹13.09 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 14%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 21Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2022The Board of Directors of Advanced Enzyme Technologies Limited at its Meeting held on May 20, 2022, Recommended a Dividend at the rate of 50% that is INR 1 per Equity Share on the face value of INR 2 each for the financial year ended March 31, 2022, subject to the approval of the Shareholders at the upcoming 33rd Annual General Meeting of the Company ("AGM"). The Dividend, if approved /declared by the Shareholders at 33rd AGM, will be paid on and from the second day from the date of AGM. Record date for the entitlement of Dividend, and date & timings for upcoming Annual General Meeting of the Company shall be intimated in due course of time.お知らせ • May 13Advanced Enzyme Technologies Limited to Report Q4, 2022 Results on May 20, 2022Advanced Enzyme Technologies Limited announced that they will report Q4, 2022 results on May 20, 2022Price Target Changed • Apr 27Price target increased to ₹380Up from ₹333, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹305. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹11.30 for next year compared to ₹13.09 last year.Valuation Update With 7 Day Price Move • Mar 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹319, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.Reported Earnings • Feb 08Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: EPS: ₹2.46 (down from ₹3.86 in 3Q 2021). Revenue: ₹1.35b (down 2.6% from 3Q 2021). Net income: ₹274.8m (down 36% from 3Q 2021). Profit margin: 20% (down from 31% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 22%, compared to a 20% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 28Advanced Enzyme Technologies Limited Announces Demise of Vilas Aurangabadkar, Independent DirectorAdvanced Enzyme Technologies Limited announces demise of Vilas Aurangabadkar, Independent Director of the Company on January 27, 2022.Recent Insider Transactions • Jan 08Insider recently sold ₹611k worth of stockOn the 31st of December, Santosh Ingale sold around 2k shares on-market at roughly ₹326 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹6.3m more than they bought in the last 12 months.Reported Earnings • Nov 03Second quarter 2022 earnings released: EPS ₹2.66 (vs ₹3.33 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹1.28b (up 5.8% from 2Q 2021). Net income: ₹297.0m (down 20% from 2Q 2021). Profit margin: 23% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 15Advanced Enzymes Announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve Long Covid' Fatigue SymptomsAdvanced Enzyme Technologies Limited announced that its systemic enzyme and probiotic supplements--ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve postCOVID fatigue symptoms. It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID19 disease. However, there are no specific treatments available globally to treat postCOVID fatigue complications. With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID19 induced fatigue, a randomized, multicentric, double blind and placebocontrolled trial was conducted in 200 patients suffering from postCOVID fatigue symptoms. The test arm (100 patients) received the oral supplements for 14days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL. The randomized clinical trial was conducted on 200 patients that did not have an active SARSCoV2 infection, as determined by a negative COVID19 test, with a complaint of postCOVID fatigue. Patients were required to have a positive COVID19 test at any time in the past. The trial was conducted across three centres in India--Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14days, informed Dr. Rathi. According to the clinical research paper published by the Switzerlandbased "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ11) for 14days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved postCOVID19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi. The Coronavirus disease19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7-10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID. Studies revealed that about 52% of patients among the studied population showed fatigue/myalgia postCOVID19. A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.Upcoming Dividend • Aug 24Upcoming dividend of ₹0.90 per shareEligible shareholders must have bought the stock before 31 August 2021. Payment date: 08 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.7%).お知らせ • Aug 19Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited.Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 15% minority stake in JC Biotech Private Limited for approximately INR 210 million on May 29, 2021. Advanced Enzyme Technologies Limited will acquire 31.1 million equity shares of JC Biotech Private Limited at a price of INR 68 per share. Post completion of the transaction, Advanced Enzyme Technologies Limited's stake in JC Biotech Private Limited will increase from 70% to 85%. For the year 2020 to 2021, JC Biotech Private Limited reported Turnover of approximately INR 500 million and Profit After Tax of INR 78 million. On May 29, 2021, Board of Directors of Advanced Enzyme Technologies Limited approved the transaction. As of May 29, 2021, Advanced Enzyme Technologies Limited has also obtained approval of the Audit Committee as well. The transaction is expected to close by September 30, 2021. Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited on August 18, 2021.Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.40 (vs ₹3.07 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹1.38b (up 24% from 1Q 2021). Net income: ₹380.4m (up 11% from 1Q 2021). Profit margin: 28% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 30Full year 2021 earnings released: EPS ₹13.09 (vs ₹11.58 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹5.11b (up 14% from FY 2020). Net income: ₹1.46b (up 13% from FY 2020). Profit margin: 29% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 30Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2021Advanced Enzyme Technologies Limited announced at the board meeting held on May 29, 2021, recommended a dividend @45%, that is INR 0.90 per equity share on the face value of INR 2 each for the financial year ended March 31, 2021, subject to the approval of the shareholders at the upcoming 32nd AGM of the company. The Dividend, if approved /declared by the Shareholders at 32nd AGM, will be paid on and from the second (2nd) day from the date of AGM.Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹449, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 82% over the past three years.Recent Insider Transactions • Feb 21Insider recently sold ₹5.7m worth of stockOn the 15th of February, Madhusudan Soni sold around 16k shares on-market at roughly ₹367 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹31m more than they sold in the last 12 months.Reported Earnings • Feb 13Third quarter 2021 earnings released: EPS ₹3.86 (vs ₹3.01 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.39b (up 23% from 3Q 2020). Net income: ₹430.9m (up 28% from 3Q 2020). Profit margin: 31% (up from 30% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹364, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.8x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 44%.Is New 90 Day High Low • Feb 08New 90-day high: ₹364The company is up 20% from its price of ₹303 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.お知らせ • Feb 02Advanced Enzyme Technologies Limited to Report Q3, 2021 Results on Feb 12, 2021Advanced Enzyme Technologies Limited announced that they will report Q3, 2021 results on Feb 12, 2021Recent Insider Transactions • Jan 07Insider recently sold ₹674k worth of stockOn the 31st of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹337 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹37m more than they sold in the last 12 months.Recent Insider Transactions • Dec 23Insider recently sold ₹695k worth of stockOn the 17th of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹348 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹37m more than they sold in the last 12 months.Recent Insider Transactions • Dec 13Insider recently sold ₹716k worth of stockOn the 9th of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹358 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹38m more than they sold in the last 12 months.Recent Insider Transactions • Nov 28Insider recently sold ₹6.7m worth of stockOn the 24th of November, Madhusudan Soni sold around 20k shares on-market at roughly ₹337 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹55m more than they sold in the last 12 months.Reported Earnings • Nov 17Second quarter 2021 earnings released: EPS ₹3.33The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹1.21b (up 7.1% from 2Q 2020). Net income: ₹371.9m (up 20% from 2Q 2020). Profit margin: 31% (up from 27% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 03Advanced Enzyme Technologies Limited to Report Q2, 2021 Results on Nov 12, 2020Advanced Enzyme Technologies Limited announced that they will report Q2, 2021 results on Nov 12, 2020Recent Insider Transactions • Oct 03Insider recently sold ₹606k worth of stockOn the 28th of September, Subhash Chakor sold around 2k shares on-market at roughly ₹303 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹693k. Despite this recent sale, insiders have collectively bought ₹62m more than they sold in the last 12 months.業績と収益の成長予測BSE:540025 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20289,9702,0537331,67813/31/20278,5351,7298761,44113/31/20267,8061,6871,0441,568N/A12/31/20257,0961,522N/AN/AN/A9/30/20257,0671,4741,3231,643N/A6/30/20256,6831,369N/AN/AN/A3/31/20256,3691,3111,0771,425N/A12/31/20246,2751,329N/AN/AN/A9/30/20246,1941,3719041,422N/A6/30/20246,3111,386N/AN/AN/A3/31/20246,2391,3339411,414N/A12/31/20236,0481,371N/AN/AN/A9/30/20235,8591,2489651,327N/A6/30/20235,6681,166N/AN/AN/A3/31/20235,4061,0561,0221,404N/A12/31/20225,337979N/AN/AN/A9/30/20225,2519608061,164N/A6/30/20225,135995N/AN/AN/A3/31/20225,2941,1969411,223N/A12/31/20215,3091,268N/AN/AN/A9/30/20215,3501,4241,1271,374N/A6/30/20215,3251,500N/AN/AN/A3/31/20215,0181,4591,4341,630N/A12/31/20204,8201,459N/AN/AN/A9/30/20204,5691,3649781,472N/A6/30/20204,4811,301N/AN/AN/A3/31/20204,4401,2939041,409N/A12/31/20194,4801,302N/AN/AN/A9/30/20194,3661,210N/A1,276N/A6/30/20194,2881,148N/AN/AN/A3/31/20194,2201,111N/A1,286N/A12/31/20184,1941,061N/AN/AN/A9/30/20184,2611,068N/AN/AN/A6/30/20184,1991,039N/AN/AN/A3/31/20183,918901N/A1,160N/A12/31/20173,660837N/AN/AN/A9/30/20173,213725N/AN/AN/A6/30/20173,127793N/AN/AN/A3/31/20173,290915N/A1,074N/A12/31/20163,260942N/AN/AN/A9/30/20163,404998N/AN/AN/A6/30/20163,184854N/AN/AN/A3/31/20162,938759N/A934N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 540025の予測収益成長率 (年間10% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: 540025の収益 ( 10% ) Indian市場 ( 16.3% ) よりも低い成長が予測されています。高成長収益: 540025の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 540025の収益 ( 12.3% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 540025の収益 ( 12.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 540025の 自己資本利益率 は、3年後には低くなると予測されています ( 12.2 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 20:49終値2026/05/22 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Advanced Enzyme Technologies Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Nandan ChakrabortyAxis Capital LimitedAbhishek NavalgundCentrum Broking Limitednull nullDBS Bank Ltd1 その他のアナリストを表示
Price Target Changed • Nov 16Price target decreased to ₹265Down from ₹333, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹274. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹8.50 for next year compared to ₹10.70 last year.
Price Target Changed • Apr 27Price target increased to ₹380Up from ₹333, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹305. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹11.30 for next year compared to ₹13.09 last year.
Reported Earnings • May 11Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: ₹15.08 (up from ₹11.72 in FY 2025). Revenue: ₹7.81b (up 23% from FY 2025). Net income: ₹1.69b (up 29% from FY 2025). Profit margin: 22% (up from 21% in FY 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year.
お知らせ • May 02Advanced Enzyme Technologies Limited to Report Q4, 2026 Results on May 09, 2026Advanced Enzyme Technologies Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 09, 2026
Valuation Update With 7 Day Price Move • Apr 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹348, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Feb 01Third quarter 2026 earnings released: EPS: ₹3.80 (vs ₹3.36 in 3Q 2025)Third quarter 2026 results: EPS: ₹3.80 (up from ₹3.36 in 3Q 2025). Revenue: ₹1.72b (up 1.7% from 3Q 2025). Net income: ₹425.0m (up 13% from 3Q 2025). Profit margin: 25% (up from 22% in 3Q 2025). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jan 23Advanced Enzyme Technologies Limited to Report Q3, 2026 Results on Jan 31, 2026Advanced Enzyme Technologies Limited announced that they will report Q3, 2026 results on Jan 31, 2026
お知らせ • Nov 04Advanced Enzyme Technologies Limited to Report Q2, 2026 Results on Nov 12, 2025Advanced Enzyme Technologies Limited announced that they will report Q2, 2026 results on Nov 12, 2025
Valuation Update With 7 Day Price Move • Aug 09Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹305, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 21% over the past three years.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Independent Director Vandana Tilak was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 25Advanced Enzyme Technologies Limited to Report Q1, 2026 Results on Aug 02, 2025Advanced Enzyme Technologies Limited announced that they will report Q1, 2026 results on Aug 02, 2025
Upcoming Dividend • Jul 16Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 23 July 2025. Payment date: 29 August 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 1.6%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).
Reported Earnings • Jul 08Full year 2025 earnings released: EPS: ₹11.72 (vs ₹11.92 in FY 2024)Full year 2025 results: EPS: ₹11.72 (down from ₹11.92 in FY 2024). Revenue: ₹6.37b (up 2.1% from FY 2024). Net income: ₹1.31b (down 1.6% from FY 2024). Profit margin: 21% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year.
Declared Dividend • Jun 11Dividend of ₹1.20 announcedShareholders will receive a dividend of ₹1.20. Ex-date: 23rd July 2025 Payment date: 29th August 2025 Dividend yield will be 1.6%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (54% cash payout ratio). The dividend has increased by an average of 38% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
Declared Dividend • May 15Dividend of ₹4.00 announcedShareholders will receive a dividend of ₹4.00. Ex-date: 16th May 2025 Payment date: 12th June 2025 Dividend yield will be 1.8%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (43% earnings payout ratio) and cash flows (63% cash payout ratio). The dividend has increased by an average of 37% per year over the past 8 years and payments have been stable during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
お知らせ • May 13+ 2 more updatesAdvanced Enzyme Technologies Limited, Annual General Meeting, Jul 30, 2025Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 30, 2025.
New Risk • Feb 13New major risk - Revenue and earnings growthEarnings have declined by 1.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Feb 09Third quarter 2025 earnings released: EPS: ₹3.36 (vs ₹3.74 in 3Q 2024)Third quarter 2025 results: EPS: ₹3.36 (down from ₹3.74 in 3Q 2024). Revenue: ₹1.69b (up 5.1% from 3Q 2024). Net income: ₹376.5m (down 9.9% from 3Q 2024). Profit margin: 22% (down from 26% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 01Advanced Enzyme Technologies Limited to Report Q3, 2025 Results on Feb 08, 2025Advanced Enzyme Technologies Limited announced that they will report Q3, 2025 results on Feb 08, 2025
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹380, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 17% over the past three years.
Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹2.94 (vs ₹3.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.94 (down from ₹3.08 in 2Q 2024). Revenue: ₹1.46b (down 7.4% from 2Q 2024). Net income: ₹328.3m (down 4.6% from 2Q 2024). Profit margin: 23% (in line with 2Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.
New Risk • Nov 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (₹52m sold).
お知らせ • Oct 31Advanced Enzyme Technologies Limited to Report Q2, 2025 Results on Nov 09, 2024Advanced Enzyme Technologies Limited announced that they will report Q2, 2025 results on Nov 09, 2024
Recent Insider Transactions • Sep 16Insider recently sold ₹51m worth of stockOn the 11th of September, Mangala Kabra sold around 100k shares on-market at roughly ₹509 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹68m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Sep 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹534, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 38% over the past three years.
Valuation Update With 7 Day Price Move • Aug 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹468, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Aug 11First quarter 2025 earnings released: EPS: ₹3.05 (vs ₹2.58 in 1Q 2024)First quarter 2025 results: EPS: ₹3.05 (up from ₹2.58 in 1Q 2024). Revenue: ₹1.62b (up 9.7% from 1Q 2024). Net income: ₹341.5m (up 19% from 1Q 2024). Profit margin: 21% (up from 20% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 2% per year.
お知らせ • Aug 02Advanced Enzyme Technologies Limited to Report Q1, 2025 Results on Aug 10, 2024Advanced Enzyme Technologies Limited announced that they will report Q1, 2025 results on Aug 10, 2024
お知らせ • Jul 27Advanced Enzyme Technologies Approves Final Dividend for the Financial Year Ended March 31, 2024Advanced Enzyme Technologies Limited at its 35th AGM held on July 25, 2024 approved final Dividend (INR 1.10 per Equity Share) on the Equity Shares of 2 each, for the financial year ended March 31, 2024.
Upcoming Dividend • Jul 11Upcoming dividend of ₹1.10 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 24 August 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 1.3%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%).
Reported Earnings • Jul 05Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.24b (up 15% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 21% (up from 20% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.
お知らせ • Jun 28Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024Advanced Enzyme Technologies Limited, Annual General Meeting, Jul 25, 2024, at 10:00 Indian Standard Time.
Recent Insider Transactions • Jun 26Insider recently sold ₹11m worth of stockOn the 20th of June, Chandrakanth Kumar Rathi sold around 29k shares on-market at roughly ₹392 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 22Insider recently sold ₹6.9m worth of stockOn the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹13m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 20Insider recently sold ₹6.9m worth of stockOn the 14th of June, Chandrakanth Kumar Rathi sold around 18k shares on-market at roughly ₹396 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹4.9m more than they bought in the last 12 months.
Declared Dividend • May 15Final dividend of ₹4.00 announcedShareholders will receive a dividend of ₹4.00. Ex-date: 17th May 2024 Payment date: 5th June 2024 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 39% per year over the past 7 years and payments have been stable during that time. Earnings per share has grown by 3.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 13Full year 2024 earnings released: EPS: ₹11.92 (vs ₹9.45 in FY 2023)Full year 2024 results: EPS: ₹11.92 (up from ₹9.45 in FY 2023). Revenue: ₹6.61b (up 22% from FY 2023). Net income: ₹1.33b (up 26% from FY 2023). Profit margin: 20% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 6% per year.
お知らせ • May 12+ 1 more updateAdvanced Enzyme Technologies Limited Recommends Final Dividend for the Financial Year 2023-2024Advanced Enzyme Technologies Limited announced that at its board meeting held on May 11, 2024, recommended a final dividend at 55% that is INR1.1 per equity share on the face value of INR 2 each for the financial year 2023-2024, subject to the approval of the Shareholders at the upcoming 35th Annual General Meeting of the Company (AGM). The final dividend, if approved /declared by the Shareholders at 35th AGM, will be paidon and from the second day from the date of AGM.
お知らせ • May 06Advanced Enzyme Technologies Limited to Report Q4, 2024 Results on May 11, 2024Advanced Enzyme Technologies Limited announced that they will report Q4, 2024 results on May 11, 2024
お知らせ • Mar 07Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) acquired additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 millionAdvanced Enzyme Technologies Limited (NSEI:ADVENZYMES) agreed to acquire additional 5.89% stake in Jc Biotech Private Limited for INR 56.1 million on February 10, 2024. Advanced Enzyme currently holds 89.83% stake in Jc Biotech and post completion of the transaction Advanced Enzyme will hold 95.72% stake in Jc Biotech. Jc Biotech reported turnover of INR 502 million and loss after tax of INR 18.42 million for FY2022-23. Board of Advanced Enzyme approved the transaction. The transaction is expected to close on March 31, 2024. Advanced Enzyme Technologies Limited (NSEI:ADVENZYMES) completed the acquisition of additional 5.89% stake in Jc Biotech Private Limited on March 5, 2024.
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹3.74 (vs ₹2.63 in 3Q 2023)Third quarter 2024 results: EPS: ₹3.74 (up from ₹2.63 in 3Q 2023). Revenue: ₹1.75b (up 23% from 3Q 2023). Net income: ₹417.7m (up 42% from 3Q 2023). Profit margin: 24% (up from 21% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Feb 05Advanced Enzyme Technologies Limited to Report Q3, 2024 Results on Feb 10, 2024Advanced Enzyme Technologies Limited announced that they will report Q3, 2024 results on Feb 10, 2024
New Risk • Dec 28New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.4% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
お知らせ • Nov 01Advanced Enzyme Technologies Limited to Report Q2, 2024 Results on Nov 07, 2023Advanced Enzyme Technologies Limited announced that they will report Q2, 2024 results on Nov 07, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: ₹2.58 (vs ₹1.60 in 1Q 2023)First quarter 2024 results: EPS: ₹2.58 (up from ₹1.60 in 1Q 2023). Revenue: ₹1.47b (up 22% from 1Q 2023). Net income: ₹288.1m (up 61% from 1Q 2023). Profit margin: 20% (up from 15% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
お知らせ • Aug 13Advanced Enzyme Technologies Declares Final Dividend for the Financial Year Ended March 31, 2023Advanced Enzyme Technologies Limited at the AGM held on August 12, 2023 declared final Dividend (INR 1 per Equity Share) on the Equity Shares of 2each, for the financial year ended March 31, 2023.
お知らせ • Aug 05Advanced Enzyme Technologies Limited to Report Q1, 2024 Results on Aug 12, 2023Advanced Enzyme Technologies Limited announced that they will report Q1, 2024 results on Aug 12, 2023
Upcoming Dividend • Jul 28Upcoming dividend of ₹1.00 per share at 1.2% yieldEligible shareholders must have bought the stock before 04 August 2023. Payment date: 11 September 2023. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%).
Reported Earnings • Jul 15Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.41b (up 2.1% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 20% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
お知らせ • Jul 09Advanced Enzyme Technologies Limited Proposes Dividend Payable on or After August 16, 2023The 34th Annual General Meeting ("AGM") of the Advanced Enzyme Technologies Limited will be held on August 12, 2023. Pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to letter dated May 13,2023 intimating that Dividend of INR 1 per Equity Share of INR 2 each for the financial year 2022-23 (FY23) recommended by the Board of Directors of the Company, it is hereby informed that Record Date has been fixed as August 05, 2023, for the purpose of ascertaining the entitlement of the Members to the said final dividend for Fiscal 2023, if approved (declared) at the 34th AGM. If the Dividend is approved by the Members as mentioned above: the said Dividend shall be paid on or after August 16, 2023 to the Members whose names appear in the Register of Members or as beneficial owners as on August 05, 2023; and in the cases where the ECS mandates of the Members are not available to enable the payment of Dividend electronically, the Dividend warrant/drafts/cheques shall be sent in due course.
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Independent Director Nitin Deshmukh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jun 18Chairman recently bought ₹142m worth of stockOn the 15th of June, Vasant Rathi bought around 515k shares on-market at roughly ₹275 per share. This transaction amounted to 1.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 05Chairman recently bought ₹2.7m worth of stockOn the 31st of May, Vasant Rathi bought around 10k shares on-market at roughly ₹275 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Vasant's only on-market trade for the last 12 months.
Reported Earnings • May 14Full year 2023 earnings: Revenues and EPS in line with analyst expectationsFull year 2023 results: EPS: ₹9.45 (down from ₹10.70 in FY 2022). Revenue: ₹5.66b (up 6.9% from FY 2022). Net income: ₹1.06b (down 12% from FY 2022). Profit margin: 19% (down from 23% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
お知らせ • May 14+ 1 more updateAdvanced Enzyme Technologies Limited Announces Board ChangesThe board of directors of Advanced Enzyme Technologies Limited meeting held on May 13, 2023, appointed Ms. Vandana R. Tilak as an Additional Director (Independent), with effect from July 01, 2023, to hold office up to the date of upcoming Annual General Meeting of the Company ("AGM") or the date up to which AGM shall be held, whichever is earlier. Subject To Approve the Members at the upcoming AGM of the Company, Ms. Vandana R. Tilak shall hold office as an Independent Director for a period of 5 (five) years effective from July 01, 2023. Ms. Vandana R. Tilak is a social entrepreneur and visionary with exceptional sales, fundraising, and marketing skills to lead teams and pivot on the ever- changing revenue generation landscape. Ms. Vandana has launched several companies in film making, Ayurveda, real estate and the family engineering firm Almex USA Inc. Almex is a niche company that provides cast house technology solutions for manufacturing aerospace grade aluminum alloys. She is currently working as Director and CEO for the Akshaya Patra Foundation USA. The Board noted that Mr. Rajesh Sharma, an Independent Director, whose tenure of five years as an Independent Director on the Board of the Company ends with effect from August 10, 2023, has conveyed his unwillingness to get re-appointed for the second term, considering his pre-occupation and increased responsibilities in his professional engagements. Accordingly, he shall cease to be Director on the Board of the Company after the expiry of his existing tenure effective from August 10, 2023.
お知らせ • May 07Advanced Enzyme Technologies Limited to Report Q4, 2023 Results on May 13, 2023Advanced Enzyme Technologies Limited announced that they will report Q4, 2023 results on May 13, 2023
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹2.63 (vs ₹2.46 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.63 (up from ₹2.46 in 3Q 2022). Revenue: ₹1.51b (up 13% from 3Q 2022). Net income: ₹294.4m (up 7.1% from 3Q 2022). Profit margin: 20% (down from 21% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
お知らせ • Feb 05Advanced Enzyme Technologies Limited to Report Q3, 2023 Results on Feb 11, 2023Advanced Enzyme Technologies Limited announced that they will report Q3, 2023 results on Feb 11, 2023
お知らせ • Jan 04Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited.Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 4.83% stake in JC Biotech Private Limited for INR 68 million on November 11, 2022. Advanced Enzyme Technologies Limited will acquire 1 million shares of JC Biotech Private Limited. JC Biotech Private Limited reported Turnover of INR 504 million and Net income of INR 73 million in year ending March 31, 2022. The transaction was approved by Advanced Enzyme Technologies Limited Board of directors. The transaction was expected to complete on January 31, 2023. Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 4.83% stake in JC Biotech Private Limited on January 3, 2022.
Price Target Changed • Nov 16Price target decreased to ₹265Down from ₹333, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of ₹274. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹8.50 for next year compared to ₹10.70 last year.
お知らせ • Nov 05Advanced Enzyme Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022Advanced Enzyme Technologies Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Nov 11, 2022
Recent Insider Transactions • Sep 23Insider recently sold ₹100m worth of stockOn the 19th of September, Savita Rathi sold around 372k shares on-market at roughly ₹270 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹101m more than they bought in the last 12 months.
お知らせ • Aug 20+ 1 more updateAdvanced Enzyme Technologies Limited Announces Appointment of Mr. Nitin Jagannath Deshmukh as an Independent Director of the CompanyAdvanced Enzyme Technologies Limited at its Annual General Meeting (AGM) held on August 19, 2022 approved appointment of Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Independent Director of the Company.
Upcoming Dividend • Aug 04Upcoming dividend of ₹1.00 per shareEligible shareholders must have bought the stock before 11 August 2022. Payment date: 18 September 2022. Payout ratio is a comfortable 9.3% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (0.7%).
お知らせ • Jul 30+ 1 more updateAdvanced Enzyme Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022Advanced Enzyme Technologies Limited proposed to declare final dividend of INR 1/- on the equity shares of INR 2/- each for the financial year ended March 31, 2022 at the annual general meeting to be held on August 19, 2022.
Reported Earnings • Jul 29Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹10.70 (down from ₹13.07 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 7.3%, compared to a 15% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 22Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022Advanced Enzyme Technologies Limited, Annual General Meeting, Aug 19, 2022, at 10:00 Indian Standard Time.
Reported Earnings • May 22Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹10.70 (down from ₹13.09 in FY 2021). Revenue: ₹5.29b (up 5.5% from FY 2021). Net income: ₹1.20b (down 18% from FY 2021). Profit margin: 23% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 14%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 21Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2022The Board of Directors of Advanced Enzyme Technologies Limited at its Meeting held on May 20, 2022, Recommended a Dividend at the rate of 50% that is INR 1 per Equity Share on the face value of INR 2 each for the financial year ended March 31, 2022, subject to the approval of the Shareholders at the upcoming 33rd Annual General Meeting of the Company ("AGM"). The Dividend, if approved /declared by the Shareholders at 33rd AGM, will be paid on and from the second day from the date of AGM. Record date for the entitlement of Dividend, and date & timings for upcoming Annual General Meeting of the Company shall be intimated in due course of time.
お知らせ • May 13Advanced Enzyme Technologies Limited to Report Q4, 2022 Results on May 20, 2022Advanced Enzyme Technologies Limited announced that they will report Q4, 2022 results on May 20, 2022
Price Target Changed • Apr 27Price target increased to ₹380Up from ₹333, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹305. Stock is down 25% over the past year. The company is forecast to post earnings per share of ₹11.30 for next year compared to ₹13.09 last year.
Valuation Update With 7 Day Price Move • Mar 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹319, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 112% over the past three years.
Reported Earnings • Feb 08Third quarter 2022 earnings: EPS misses analyst expectationsThird quarter 2022 results: EPS: ₹2.46 (down from ₹3.86 in 3Q 2021). Revenue: ₹1.35b (down 2.6% from 3Q 2021). Net income: ₹274.8m (down 36% from 3Q 2021). Profit margin: 20% (down from 31% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 22%, compared to a 20% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 28Advanced Enzyme Technologies Limited Announces Demise of Vilas Aurangabadkar, Independent DirectorAdvanced Enzyme Technologies Limited announces demise of Vilas Aurangabadkar, Independent Director of the Company on January 27, 2022.
Recent Insider Transactions • Jan 08Insider recently sold ₹611k worth of stockOn the 31st of December, Santosh Ingale sold around 2k shares on-market at roughly ₹326 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹6.3m more than they bought in the last 12 months.
Reported Earnings • Nov 03Second quarter 2022 earnings released: EPS ₹2.66 (vs ₹3.33 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹1.28b (up 5.8% from 2Q 2021). Net income: ₹297.0m (down 20% from 2Q 2021). Profit margin: 23% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 15Advanced Enzymes Announces Positive Clinical Breakthrough in the Randomized Controlled Trials of Systemic Enzymes and Probiotics to Resolve Long Covid' Fatigue SymptomsAdvanced Enzyme Technologies Limited announced that its systemic enzyme and probiotic supplements--ImmunoSEB and ProbioSEB CSC3 have passed the promising stages of randomized controlled clinical trials in terms of efficacy to resolve postCOVID fatigue symptoms. It's a fact that muscle fatigue and cognitive disturbances persist in patients after recovery from acute COVID19 disease. However, there are no specific treatments available globally to treat postCOVID fatigue complications. With an aim to evaluate the efficacy and safety of the health supplements ImmunoSEB (systemic enzyme complex) and ProbioSEB CSC3 (probiotic complex) in patients suffering from COVID19 induced fatigue, a randomized, multicentric, double blind and placebocontrolled trial was conducted in 200 patients suffering from postCOVID fatigue symptoms. The test arm (100 patients) received the oral supplements for 14days and the control arm (100 patients) received placebo, informed Dr. Abhijit K. Rathi, Principal Scientist, AETL. The randomized clinical trial was conducted on 200 patients that did not have an active SARSCoV2 infection, as determined by a negative COVID19 test, with a complaint of postCOVID fatigue. Patients were required to have a positive COVID19 test at any time in the past. The trial was conducted across three centres in India--Swasthya Hospital, Bhopal; Samvedna Hospital, Varanasi; and Chirayu Medical College & Hospital, Bhopal by Investigators for 14days, informed Dr. Rathi. According to the clinical research paper published by the Switzerlandbased "Medicines" Journal on August 30, 2021, the treatment efficacy was compared using the Chalder Fatigue Scale (CFQ11) for 14days. Interestingly, the supplemental treatment resulted in resolution of fatigue in a greater percentage in patients during the test as against the control arm (91% vs. 15%) during the 14day trial. Patients in the test arm category showed a significantly greater reduction the overall physical and mental fatigue scores as against patients in the control arm segment. The supplements were well tolerated with no adverse events reported. This clinical study demonstrated that the 14day supplementation of ImmunoSEB and ProbioSEB CSC3 resolved postCOVID19 fatigue symptoms and improved patients' functional status and quality of life, informed Dr. Rathi. The Coronavirus disease19 (COVID19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2), is a worldwide pandemic afflicting a large population across the globe. Most infected people develop acute symptoms that last for 7-10 days. However, one or more symptoms (physical, cognitive and/or psychological) persist for weeks or even months in a substantial percentage of people. Fatigue is the most persistent and debilitating symptom of long COVID. Studies revealed that about 52% of patients among the studied population showed fatigue/myalgia postCOVID19. A survey done by the Office for National Statistics (ONS), United Kingdom suggests that about one in five people have symptoms of long COVID five weeks after an initial infection and one in ten after twelve weeks. The chronic phase of COVID19 is conjectured to be perpetual, with impaired functional status and quality of life. Though the data on COVID fatigue is still emerging, viral infections are known to trigger chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME) in patients. There are no specific biomarkers, and diagnosis is typically based on symptoms.
Upcoming Dividend • Aug 24Upcoming dividend of ₹0.90 per shareEligible shareholders must have bought the stock before 31 August 2021. Payment date: 08 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.7%).
お知らせ • Aug 19Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited.Advanced Enzyme Technologies Limited (BSE:540025) agreed to acquire additional 15% minority stake in JC Biotech Private Limited for approximately INR 210 million on May 29, 2021. Advanced Enzyme Technologies Limited will acquire 31.1 million equity shares of JC Biotech Private Limited at a price of INR 68 per share. Post completion of the transaction, Advanced Enzyme Technologies Limited's stake in JC Biotech Private Limited will increase from 70% to 85%. For the year 2020 to 2021, JC Biotech Private Limited reported Turnover of approximately INR 500 million and Profit After Tax of INR 78 million. On May 29, 2021, Board of Directors of Advanced Enzyme Technologies Limited approved the transaction. As of May 29, 2021, Advanced Enzyme Technologies Limited has also obtained approval of the Audit Committee as well. The transaction is expected to close by September 30, 2021. Advanced Enzyme Technologies Limited (BSE:540025) completed the acquisition of additional 15% minority stake in JC Biotech Private Limited on August 18, 2021.
Reported Earnings • Aug 09First quarter 2022 earnings released: EPS ₹3.40 (vs ₹3.07 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹1.38b (up 24% from 1Q 2021). Net income: ₹380.4m (up 11% from 1Q 2021). Profit margin: 28% (down from 31% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 30Full year 2021 earnings released: EPS ₹13.09 (vs ₹11.58 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: ₹5.11b (up 14% from FY 2020). Net income: ₹1.46b (up 13% from FY 2020). Profit margin: 29% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 30Advanced Enzyme Technologies Limited Recommends Dividend for the Financial Year Ended March 31, 2021Advanced Enzyme Technologies Limited announced at the board meeting held on May 29, 2021, recommended a dividend @45%, that is INR 0.90 per equity share on the face value of INR 2 each for the financial year ended March 31, 2021, subject to the approval of the shareholders at the upcoming 32nd AGM of the company. The Dividend, if approved /declared by the Shareholders at 32nd AGM, will be paid on and from the second (2nd) day from the date of AGM.
Valuation Update With 7 Day Price Move • May 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹449, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 82% over the past three years.
Recent Insider Transactions • Feb 21Insider recently sold ₹5.7m worth of stockOn the 15th of February, Madhusudan Soni sold around 16k shares on-market at roughly ₹367 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹31m more than they sold in the last 12 months.
Reported Earnings • Feb 13Third quarter 2021 earnings released: EPS ₹3.86 (vs ₹3.01 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.39b (up 23% from 3Q 2020). Net income: ₹430.9m (up 28% from 3Q 2020). Profit margin: 31% (up from 30% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₹364, the stock is trading at a trailing P/E ratio of 29.8x, up from the previous P/E ratio of 25.8x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 44%.
Is New 90 Day High Low • Feb 08New 90-day high: ₹364The company is up 20% from its price of ₹303 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 12% over the same period.
お知らせ • Feb 02Advanced Enzyme Technologies Limited to Report Q3, 2021 Results on Feb 12, 2021Advanced Enzyme Technologies Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Recent Insider Transactions • Jan 07Insider recently sold ₹674k worth of stockOn the 31st of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹337 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹37m more than they sold in the last 12 months.
Recent Insider Transactions • Dec 23Insider recently sold ₹695k worth of stockOn the 17th of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹348 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹37m more than they sold in the last 12 months.
Recent Insider Transactions • Dec 13Insider recently sold ₹716k worth of stockOn the 9th of December, Madhusudan Soni sold around 2k shares on-market at roughly ₹358 per share. In the last 3 months, they made an even bigger sale worth ₹6.7m. Despite this recent sale, insiders have collectively bought ₹38m more than they sold in the last 12 months.
Recent Insider Transactions • Nov 28Insider recently sold ₹6.7m worth of stockOn the 24th of November, Madhusudan Soni sold around 20k shares on-market at roughly ₹337 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹55m more than they sold in the last 12 months.
Reported Earnings • Nov 17Second quarter 2021 earnings released: EPS ₹3.33The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹1.21b (up 7.1% from 2Q 2020). Net income: ₹371.9m (up 20% from 2Q 2020). Profit margin: 31% (up from 27% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 03Advanced Enzyme Technologies Limited to Report Q2, 2021 Results on Nov 12, 2020Advanced Enzyme Technologies Limited announced that they will report Q2, 2021 results on Nov 12, 2020
Recent Insider Transactions • Oct 03Insider recently sold ₹606k worth of stockOn the 28th of September, Subhash Chakor sold around 2k shares on-market at roughly ₹303 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹693k. Despite this recent sale, insiders have collectively bought ₹62m more than they sold in the last 12 months.